An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator*s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
- Conditions
- Non-small cell lung cancer (NSCLC)10038666
- Registration Number
- NL-OMON44891
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 21
- ECOG Performance Status of less than or equal to 1.
- Subjects with histologically confirmed Stage IV or recurrent NSCLC, squamous or nonsquamous histology, with no prior systemic anticancer therapy (including EGFR and ALK inhibitors) given as primary therapy for advanced or metastatic disease. Prior adjuvant or neoadjuvant chemotherapy is permitted as long as the last administration of the prior regimen occurred at least 6 months prior to enrollment.
- Measurable disease by CT or MRI per RECIST 1.1 criteria.
- Subjects must be PD-L1+ on IHC testing performed by the central lab during the Screening period.
- Men and women, ages 18 years of age and above.
- Subjects with known EGFR mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution mutations) are excluded. All subjects with non-squamous histology must have been tested for EGFR mutation status; use of an FDA-approved test is strongly encouraged. Non-squamous subjects with unknown or indeterminate EGFR status are excluded.
- Subjects with known ALK translocations which are sensitive to available targeted inhibitor therapy are excluded. If tested, use of an FDA-approved test is strongly encouraged. Subjects with unknown or indeterminate ALK status may be enrolled.
- Subjects with untreated CNS metastases are excluded. Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of less than or equal to 10 mg daily prednisone (or equivalent).
- Subjects with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
- Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective is to compare the Progression Free Survival, based on<br /><br>Independent Radiographic Review, of nivolumab monotherapy versus investigator<br /><br>choice chemotherapy in subjects with stage IV or recurrent NSCLC with strongly<br /><br>positive PD-L1 tumour expression.</p><br>
- Secondary Outcome Measures
Name Time Method <p>• To compare the objective response rate (ORR), based on IRRC assessment, of<br /><br>nivolumab monotherapy and investigator*s choice chemotherapy in subjects with<br /><br>stage IV or recurrent NSCLC with strongly PD-L1+ tumor expression.<br /><br>• To compare the PFS, based on IRRC assessment, of nivolumab monotherapy with<br /><br>investigator*s choice chemotherapy in subjects with stage IV or recurrent NSCLC<br /><br>with any PD-L1+ tumor expression.<br /><br>• To compare overall survival (OS) associated with nivolumab monotherapy and<br /><br>investigator*s choice chemotherapy in subjects with stage IV or recurrent NSCLC<br /><br>with strongly PD-L1+ tumor expression.<br /><br>• To evaluate the proportion of randomized subjects exhibiting disease-related<br /><br>symptom improvement by 12 weeks as measured by the Lung Cancer Symptom Score<br /><br>(LCSS) in the nivolumab monotherapy arm and the investigator*s choice<br /><br>chemotherapy arm.</p><br>